M.P.H., Johns Hopkins University, Hygiene and Public Health, 1988.
M.D., Harvard University, Medical School, 1985.
Ph.D., Massachusetts Institute of Technology, Biology, 1981.
B.Sc., McGill University, Biochemistry, 1974.
Dr. Duerr trained in laboratory science, medicine, and infectious disease epidemiology. Throughout her career, Dr. Duerr has been interested in the public health concerns of the developing world. She began her career doing field and bench research on malaria and schistosomiasis, and for more than 15 years she has focused on clinical and epidemiological studies of HIV infection. Dr. Duerr is currently the Associate Director (Scientific Support) of the NIAID-supported HIV Vaccine Trials Network (HVTN). The HVTN is an international partnership of research scientists, clinical trial sites, and community representatives working with industry and governments to speed the development and testing of preventive HIV vaccine candidates. With more than 25 sites on 5 continents, the HVTN provides a clinical trials platform for the conduct of safety, immunogenicity, and efficacy studies of HIV vaccine candidates. Prior to joining the HVTN, Dr. Duerr served as HIV Section Chief of the Women’s Health and Fertility Branch at the Centers for Disease Control and Prevention, where she spent 13 years conducting clinical-epidemiological research on HIV infection, particularly in relation to women’s reproductive health.
Research interests include:
- HIV vaccine trials – The pipeline of potential HIV vaccine candidates continues to grow. The HVTN is currently conducting more than 10 phase I/II clinical trials and anticipates several phase IIB or proof-of-concept trials in 2005. The most promising of these candidates are vaccines that elicit cytotoxic T cell responses which, while unlikely to confer sterilizing immunity, may slow progression of HIV disease and reduce infectiousness in vaccinees who do become infected. Dr. Duerr is particularly interested in the following areas of HIV vaccine research: (1) the logistics of conducting trials in resource-poor settings where the infrastructure to support trial conduct is often poorly developed, (2) how best to measure the efficacy of vaccines that may alter clinical course of HIV infection, without preventing infection itself, and (3) elucidation of factors, such as induction of local mucosal immunity, that contribute to the prevention of sexual transmission of HIV.
- HIV infection and women’s health – Historically, Dr. Duerr has had an interest in factors associated with HIV transmission to women and in the clinical course of HIV infection in women (including the effect of HIV infection on gynecologic conditions such as vaginal infections and HPV-related cervical neoplasia). Recent work has included intervention trials, conducted in Africa, for the prevention of HIV transmission from mothers to their infants through breastfeeding, and trials in the US and Africa testing the utility of physical barriers (such as the diaphragm) and microbicides for the prevention of transmission of STDs and HIV.
- Refugee Health – Much research in refugee health has focused on the importance of infectious disease in complex humanitarian emergencies. Reproductive health has received less attention; maternal mortality and neonatal deaths may be under-reported. Dr. Duerr and colleagues conducted two studies in stabilized refugee settings which found high rates of maternal and neonatal mortality; in one study, the strong association of maternal death with barriers to access to health care suggests opportunities for reducing mortality among refugee women and their children.
(Reading, Writing, Speaking)
French: (Basic, Basic, Functional)
American College of Preventive Medicine
Infectious Diseases Society of America
International AIDS Society
Honors and Awards
2000, Certificate of Appreciation for excellence in Mentoring, Association of Schools of Public Health, Schools of Public Health
2000, Certificate of Appreciation for outstanding performance in Research, NCCDPHP/CDC, Center for Disease Control, Epidemiology and Laboratory
2000, Certificate of Appreciation for outstanding performance in International Health, NCCDPHP/CDC, Center for Disease Control, International Health
1995, Special Recognition Award, Public Health Service, Public Health Service, Rwandan Refugee Response Group
1992, Surgeon General's Exemplary Service Award, United States Department of Health and Human Services (DHHS)
1991-2003, Section Chief, Centers for Disease Control and Prevention, Women's Health and Fertility Branch, HIV
1987, Staff Physician, Whitney Young Health Center
Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.. 2013.
HIV treatment as protection: next steps.. Current opinion in HIV and AIDS. 7(2):97-8.. 2012.
Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266.. 2012.
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67.. 2012.
Antiretroviral treatment in resource-limited settings 2012.. AIDS research and treatment. 2012:346708.. 2012.
Comparing Measures of Late HIV Diagnosis in Washington State.. AIDS research and treatment. 2012:182672.. 2012.
An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).. The Journal of infectious diseases. 203(6):765-72.. 2011.
Frequencies of IL10 SNP genotypes by multiplex PCR-SSP and their association with viral load and CD4 counts in HIV-1-infected Thais.. Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand. 29(1):94-101.. 2011.
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.. Nature medicine. 17(3):366-71.. 2011.
Assessing male condom failure and incorrect use.. Sexually transmitted diseases. 38(7):580-6.. 2011.
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.. AIDS (London, England). 25(2):153-8.. 2011.
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.. AIDS research and human retroviruses. 27(5):557-567.. 2011.
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.. Current opinion in HIV and AIDS. 5(5):357-61.. 2010.
Update on mucosal HIV vaccine vectors.. Current opinion in HIV and AIDS. 5(5):397-403.. 2010.
High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding.. Obstetrics and gynecology. 115(6):1150-8.. 2010.
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.. Journal of virology. 84(1):630-8.. 2010.
The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology.. Obstetrics and gynecology. 113(1):26-31.. 2009.
The potential role of biomarkers in HIV preventive vaccine trials.. Journal of acquired immune deficiency syndromes (1999). 51(5):536-45.. 2009.